Antibiotic Resistance: New enzyme- and microbiota-based therapies to combat bacterial infections
On the occasion of World Antimicrobial Resistance Awareness Week, we highlight the research being carried out by Telum Therapeutics and Microviable Therapeutics, two companies developing new strategies to combat antibiotic-resistant bacterial infections through bacteriophage-derived enzymes and treatments based on the intestinal microbiota.
Antimicrobial resistance has become one of the greatest challenges to global public health. The ability of bacteria and other microorganisms to develop resistance to the medicines used to combat them undermines the effectiveness of treatments, makes infections more difficult to control and jeopardises numerous medical procedures that depend on the availability of effective antimicrobials.
According to estimates from the Global Research on Antimicrobial Resistance (GRAM) study, published in The Lancet in 2024, in 2021, bacterial antimicrobial resistance was directly responsible for 1.14 million deaths worldwide and associated with 4.71 million deaths. The study's projections warn that, between 2025 and 2050, more than 39 million deaths could be directly attributable to bacterial resistance if efforts to combat it are not intensified. According to the latest data from the World Health Organization (WHO), antimicrobial resistance could also cost the global economy more than $3.4 trillion.
In Spain, antibiotic resistance also represents a major public health challenge. According to data published by the Spanish Ministry of Health in the Official State Gazette (BOE) in July 2025, an estimated 4,000 people die each year from infections caused by resistant bacteria. Furthermore, the latest data from the European Centre for Disease Prevention and Control (ECDC) show that, between 2019 and 2024, the incidence of bloodstream infections caused by Escherichia coli resistant to third-generation cephalosporins increased by 58.8%. This situation contrasts with progress in the prudent use of antibiotics: according to the Spanish Agency for Medicines and Medical Devices (AEMPS), antibiotic consumption in human healthcare fell by 5.1% in 2025, representing a cumulative reduction of 18.8% since 2015.
On the occasion of World Antimicrobial Resistance Awareness Week, held from 18 to 24 November, the Spanish Bioindustry Association (AseBio) highlights the work of two of its members, Telum Therapeutics and Microviable Therapeutics, which are researching and developing innovative solutions to address this public health challenge.
Bacteriophage-Derived Enzymes: New Alternatives Against Resistant Bacteria
The growing ability of bacteria to develop resistance to treatments is driving the search for new antimicrobial strategies with mechanisms of action that differ from those of conventional antibiotics. Although these medicines remain essential for combating infections, the emergence of multidrug-resistant bacteria is increasingly limiting the available therapeutic options and highlighting the need to expand the range of tools available to tackle them.
In this context, bacteriophage-derived lytic enzymes represent one of the most promising areas of research. Bacteriophages are viruses that naturally infect bacteria and use certain enzymes to destroy their cell walls. Harnessing this ability makes it possible to develop proteins with the potential to become new antimicrobial medicines.
As Roberto Díez, founder of Telum Therapeutics, explains, “the aim is not to replace conventional antibiotics, which will remain essential, but to expand the tools available to us to combat infections, particularly those caused by multidrug-resistant bacteria.”
One of the main potential advantages of these enzymes lies in their ability to act directly on essential bacterial structures. Furthermore, protein engineering makes it possible to modify and combine different components to design enzymes with specific properties against particular microorganisms. Although this approach does not eliminate the possibility of new resistance emerging, it offers mechanisms of action that could complement existing treatments.
Telum Therapeutics is developing a new generation of antimicrobials based on enzymes specifically designed to combat antibiotic-resistant bacteria. To achieve this, the company has created APEXp®, a technology platform that uses its own libraries of natural enzyme components to identify the most suitable combinations and design new proteins tailored to specific bacteria.
Its lead candidate, EPLETTX1, targets Acinetobacter baumannii, a bacterium capable of causing serious infections, particularly pneumonia in hospitalised patients. So far, the company has obtained promising preclinical results, demonstrating activity against resistant bacteria in both laboratory studies and experimental infection models. In parallel, it continues to investigate new enzymes targeting other resistant microorganisms.
Telum Therapeutics is currently advancing the preclinical development of EPLETTX1 and addressing one of the main challenges at this stage: manufacturing the medicine at a sufficient scale and to the quality standards required to complete the regulatory studies preceding clinical trials. The company aims to begin its first studies in humans in early 2028.
However, the development of new antimicrobials also presents significant economic challenges, given the lengthy research processes, the investment required and the importance of ensuring the responsible use of these treatments. In Díez's words, “the real challenge is not simply to discover a technology capable of destroying resistant bacteria, but to turn it into a safe, effective and accessible medicine for those who need it.”
The Potential of the Microbiome to Combat Antibiotic-Resistant Infections
Research into the human microbiome is opening up new possibilities for developing treatments against infections caused by antibiotic-resistant bacteria. Understanding the microorganisms that naturally inhabit our bodies and their role in health has made it possible to explore new therapeutic strategies based on the intestinal microbiota, with the aim of eliminating resistant pathogens and preventing infections from recurring.
As Claudio Hidalgo, Scientific Co-founder and Managing Director of Microviable Therapeutics, explains, one of the most advanced applications of this approach is the treatment of Clostridioides difficile infections, where microbiota transplantation from healthy donors has demonstrated its ability to eliminate the pathogen responsible for the infection. This line of research is being extended to other resistant microorganisms, such as Escherichia coli, Klebsiella pneumoniae and Enterococcus, which are responsible for urinary tract infections, surgical site infections and bloodstream infections, among others. Microbiota-derived products are being investigated both as a complement to antibiotics and as a means of preventing infections in critically ill patients, and could eventually become first-line treatments in certain cases.
In this field, Microviable Therapeutics is developing two experimental medicines based on live bacteria naturally present in the intestinal microbiota. Both are administered as oral capsules and aim to offer new alternatives for difficult-to-treat infections.
The first, MVT-201, is an ultrap urified product containing the intestinal microbiota of healthy donors, which has demonstrated over 98% efficacy in animal models in eliminating multidrug-resistant bacteria. Its mechanism of action is based on competitive exclusion, involving the production of antimicrobial substances by the bacteria present in the product and competition for nutrients and ecological niches. It has also demonstrated the ability to reduce local inflammation.
One of the main characteristics of MVT-201 is its potential to eliminate multidrug-resistant bacteria from the intestinal reservoir and thereby prevent recurrent infections. The product has completed its development phase and is currently undergoing regulatory evaluation, with the aim of progressing towards clinical trials to assess its efficacy in patients.
Meanwhile, MVT-3501 is a live biotherapeutic product consisting of a defined consortium of previously studied and characterised bacterial strains, designed to act together against resistant pathogens. It is currently in the preclinical stage, where its potential against different microorganisms is being evaluated. Its design allows for the possibility of large-scale manufacturing through fermentation processes to meet the needs of a greater number of patients.
However, the development of microbiota-derived medicines presents significant scientific, industrial and regulatory challenges. Manufacturing and ensuring the stability of these treatments is particularly complex because they contain oxygen-sensitive anaerobic bacteria, while their composition and mechanisms of action create difficulties in adapting them to existing regulatory frameworks.
These barriers are compounded by the need for funding to support their clinical development. As Hidalgo warns, “infectious diseases and, consequently, antibiotic resistance are an underfunded field, both publicly and privately, which continues to struggle to attract the momentum and funding it needs.” Overcoming these obstacles will be essential to translating the potential of these new therapeutic strategies into benefits for patients.
The work of Telum Therapeutics and Microviable Therapeutics illustrates how biotechnology is exploring new approaches to tackling antimicrobial resistance, from developing enzymes capable of combating resistant bacteria to harnessing the therapeutic potential of the intestinal microbiota. Although these solutions still face significant scientific, clinical and regulatory challenges, their progress highlights the importance of promoting research and innovation to expand therapeutic options against one of the greatest threats to global public health.